13F filer · CIK 1687078
MPM BIOIMPACT LLC
BOSTON, MA · filing since Q4 2019 · last filing Aug 14, 2026
Reported value
$1.6B
+$345.1M vs prior
Positions
37
New / sold out
7 / 11
Added / reduced
7 / 22
Turnover
19.7%
buys $289.8M · sells $335.2M
Top-10 weight
55.3%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | Ultragenyx Pharmaceuticals, Inc. | +1,418,215 | – | +$47.4M |
| New | BIOAGE Labs Inc | +1,667,661 | – | +$40.9M |
| Added | Cullinan Therapeutics, Inc. | +2,083,073 | +27.2% | +$37.9M |
| New | Taysha Gene Therapies, Inc. | +4,500,000 | – | +$30.6M |
| Added | Abivax SA | +229,079 | +213.6% | +$30.5M |
| New | Zura Bio Ltd. | +4,472,843 | – | +$26.4M |
| New | Adlai Nortye Ltd | +1,936,291 | – | +$22.3M |
| New | Annexon Inc | +3,544,354 | – | +$20.2M |
| Added | Dyne Therapeutics, Inc. | +513,941 | +36.5% | +$11.4M |
| New | Entrada Therapeutics, Inc. | +1,253,053 | – | +$9.2M |
4 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | Agios Pharmaceuticals Inc | -1,306,261 | -100.0% | $-44.2M |
| Sold out | Xenon Pharmaceuticals Inc | -588,706 | -100.0% | $-34.2M |
| Sold out | Evommune Inc | -1,455,863 | -100.0% | $-33.5M |
| Sold out | Cytokinetics Inc | -500,000 | -100.0% | $-33.0M |
| Reduced | DBV Technologies S A | -1,547,077 | -29.7% | $-25.4M |
| Sold out | Corvus Pharmaceuticals Inc | -1,674,875 | -100.0% | $-24.5M |
| Reduced | Corcept Therapeutics, Inc. | -214,672 | -21.8% | $-18.7M |
| Sold out | Climb Bio Inc | -2,593,439 | -100.0% | $-17.8M |
| Sold out | Arcutis Biotherapeutics Inc | -733,966 | -100.0% | $-17.3M |
| Sold out | Zymeworks, Inc. | -565,249 | -100.0% | $-14.2M |
23 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Cullinan Therapeutics, Inc.230031106 | 9,731,341 | $177.2M | 10.81% |
| 2 | Aktis Oncology, Inc.01021M104 | 4,835,872 | $155.9M | 9.50% |
| 3 | Liquidia Corporation53635D202 | 1,386,174 | $110.5M | 6.74% |
| 4 | Revolution Medicines, Inc.76155X100 | 492,483 | $92.2M | 5.62% |
| 5 | Corcept Therapeutics, Inc.218352102 | 771,028 | $67.0M | 4.09% |
| 6 | Edgewise Therapeutics Inc28036F105 | 1,620,780 | $65.9M | 4.02% |
| 7 | Travere Therapeutics Inc89422G107 | 1,122,731 | $63.8M | 3.89% |
| 8 | DBV Technologies S A23306J309 | 3,666,284 | $60.1M | 3.67% |
| 9 | Trevi Therapeutics Inc89532M101 | 3,073,577 | $57.3M | 3.50% |
| 10 | Alumis Inc022307102 | 2,019,020 | $56.8M | 3.46% |
27 more rows. Subscribe for $29/month to see every row, download the data and use the API.